Brugada syndrome (BrS) was first described in 1992 as an aberrant pattern of ST segment
elevation in right precordial leads with a high incidence of sudden cardiac death (SCD) in …

Background—There is emerging evidence that localization and elimination of abnormal
electric activity in the epicardial right ventricular outflow tract may be beneficial in patients …

Background Ablation approaches have been described for the management of symptomatic
ventricular arrhythmias in patients with Brugada syndrome, but this treatment is still …

The Transient Receptor Potential Melastatin 4 (TRPM4) is a transmembrane N‐glycosylated
ion channel that belongs to the large family of TRP proteins. It has an equal permeability to …

2 Belhassen Alternatives to ICD Therapy for Brugada Syndrome the BrS population. 12
Therefore, some workers included their patients with neurocardiogenic syncope in the …

Abstract Background Patients with Brugada syndrome (BrS) may experience recurrent
ventricular arrhythmias (VAs). Catheter ablation is becoming an emerging paradigm for …

expect the amount of pericardial fluid during the second mapping after flecainide to be larger
than that at baseline mapping; the longer the operator spent time mapping at baseline, the …

Arrhythmogenic cardiomyopathy (ACM) is a group of arrhythmogenic disorders of the
myocardium that are not caused by ischemic, hypertensive, or valvular heart disease. The …

A 34-year-old man with Brugada syndrome (BrS) presented with electrical storm, manifested
as multiple appropriate shocks from his implantable cardioverter-defibrillator over a period of …

Patients with Brugada syndrome are at risk of life‐threatening ventricular arrhythmias.
Epicardial substrate ablation for Brugada syndrome has been described as a means of …